Skip to main content
. 2018 May 26;32:31–42. doi: 10.1016/j.ebiom.2018.05.023

Fig. 7.

Fig. 7

The therapeutic effect of BA-MSCs treated with 66PR on IBD mice.

(a) The experimental animal scheme. (b) The clinical scores of the three groups of colitis mice. (c) The colon length of colitis mice transplanted with 66PR- or mock-treated BA-MSCs. (d) H&E stained colon section from colitis mice transplanted with 66PR- or mock-treated BA-MSCs. (e) The histological scores of colitis mice transplanted with 66PR- or mock-treated BA-MSCs. (f) The location of nuclei (DAPI, blue) staining and 66PR- or mock-treated CFSE+BA-MSCs. Eight sections were observed per group. (g) CFSE+ foci analysis of 66PR- or mock-treated BA-MSCs. (h) Flow plots of the CFSE staining in colons from colitis mice injected with 66PR- or mock-treated BA-MSCs. (i) Quantity of CFSE+ cells according to (h). PBS: injection with PBS; MSC: transplantation with BA-MSCs; MSCs(66PR): transplantation with MSCs treated with 66PR. Each experiment represents at least four mice per group. Mean ± SD, t-test, *P < 0.05,**P < 0.01,***P < 0.001.